To determine whether AKT activity is required for chemotherapeutic drug-induced expression of HIF-1α and ACE2, we first treated parental breast cancer cells with the AKT inhibitor MK-2206 to determine the expression of AKT and HIF-1α and ACE2. This evidence concerns the gene HIF1A and breast carcinoma.